US Patent

US7799336 — Hypotensive lipid-containing biodegradable intraocular implants and related methods

Formulation · Assigned to Allergan Inc · Expires 2029-04-24 · 3y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects biocompatible intraocular implants that release a prostamide component, such as bimatoprost, for an extended period to treat or reduce symptoms of ocular conditions.

USPTO Abstract

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number
US7799336
Jurisdiction
US
Classification
Formulation
Expires
2029-04-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.